Trebananib: Phase III data

Top-line data from the double-blind, international Phase III TRINOVA-1 trial in over 900 women with recurrent partially platinum-sensitive or platinum-resistant ovarian cancer, primary peritoneal cancer or fallopian tube

Read the full 281 word article

User Sign In